Please use this identifier to cite or link to this item:
|Title:||VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer|
|Source:||Hart, S., Novotny-Diermayr, V., Goh, K.C., Williams, M., Tan, Y.C., Ong, L.C., Cheong, A., Ng, B.K., Amalini, C., Madan, B., Nagaraj, H., Jayaraman, R., Pasha, K.M., Ethirajulu, K., Chng, W.J., Mustafa, N., Goh, B.C., Benes, C., McDermott, U., Garnett, M., Dymock, B., Wood, J.M. (2013-02). VS-5584, a novel and highly selective PI3K/mTOR kinase inhibitor for the treatment of cancer. Molecular Cancer Therapeutics 12 (2) : 151-161. ScholarBank@NUS Repository. https://doi.org/10.1158/1535-7163.MCT-12-0466|
|Abstract:||Dysregulation of the PI3K/mTOR pathway, either through amplifications, deletions, or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers. Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies. Here, we describe VS-5584, a novel, low-molecular weight compound with equivalent potent activity against mTOR (IC50 = 37 nmol/L) and all class I phosphoinositide 3-kinase (PI3K) isoforms IC50: PI3Ka = 16 nmol/L; PI3Kβ = 68 nmol/L; PI3Kγ = 25 nmol/L; PI3Kσ = 42 nmol/L, without relevant activity on 400 lipid and protein kinases. VS-5584 shows robust modulation of cellular PI3K/mTOR pathways, inhibiting phosphorylation of substrates downstream of PI3K and mTORC1/2. A large human cancer cell line panel screen (436 lines) revealed broad antiproliferative sensitivity and that cells harboring mutations in PI3KCA are generally more sensitive toward VS-5584 treatment. VS-5584 exhibits favorable pharmacokinetic properties after oral dosing in mice and is well tolerated. VS-5584 induces long-lasting and dose-dependent inhibition of PI3K/mTOR signaling in tumor tissue, leading to tumor growth inhibition in various rapalog-sensitive and -resistant human xenograft models. Furthermore, VS-5584 is synergistic with an EGF receptor inhibitor in a gastric tumor model. The unique selectivity profile and favorable pharmacologic and pharmaceutical properties of VS-5584 and its efficacy in a wide range of human tumor models supports further investigations of VS-5584 in clinical trials. © 2012 American Association for Cancer Research.|
|Source Title:||Molecular Cancer Therapeutics|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
There are no files associated with this item.
checked on Jan 15, 2018
WEB OF SCIENCETM
checked on Jan 15, 2018
checked on Jan 12, 2018
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.